Document is current
Any future updates will be listed below
-
Authors
Xiong, Yunyun https://orcid.org/0000-0003-1353-2295
Campbell, Bruce C V
Fisher, Marc
Schwamm, Lee H
Parsons, Mark
Li, Hao https://orcid.org/0000-0002-8591-4105
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Meng, Xia
Zhao, Xingquan https://orcid.org/0000-0001-8345-5147
Wang, Yongjun https://orcid.org/0000-0002-9976-2341
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05141305 at ClinicalTrials.govnct03785678 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials
https://doi.org/10.1136/svn-2023-002396
nct04797013 at ClinicalTrials.govDocuments that mention this clinical trial
Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research
https://doi.org/10.1136/svn-2021-001134
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Evaluating the concordance between International Classification of Diseases, Tenth Revision Code and stroke severity as measured by the National Institutes of Health Stroke Scale
https://doi.org/10.1136/bmjno-2024-000831
European Stroke Organisation (ESO)–European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion
https://doi.org/10.1136/neurintsurg-2021-018589
Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials
https://doi.org/10.1136/svn-2023-002396
Strategy for reliable identification of ischaemic stroke, thrombolytics and thrombectomy in large administrative databases
https://doi.org/10.1136/svn-2020-000533
Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial
https://doi.org/10.1136/bmj-2025-085810
Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial
https://doi.org/10.1136/svn-2025-004432
nct03785678 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design
https://doi.org/10.1136/svn-2021-001074
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial
https://doi.org/10.1136/svn-2024-003726
Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
https://doi.org/10.1136/svn-2023-002694
nct04454788 at ClinicalTrials.govDocuments that mention this clinical trial
Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research
https://doi.org/10.1136/svn-2021-001134
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Evaluating the concordance between International Classification of Diseases, Tenth Revision Code and stroke severity as measured by the National Institutes of Health Stroke Scale
https://doi.org/10.1136/bmjno-2024-000831
European Stroke Organisation (ESO)–European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion
https://doi.org/10.1136/neurintsurg-2021-018589
Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials
https://doi.org/10.1136/svn-2023-002396
Strategy for reliable identification of ischaemic stroke, thrombolytics and thrombectomy in large administrative databases
https://doi.org/10.1136/svn-2020-000533
Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial
https://doi.org/10.1136/bmj-2025-085810
Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial
https://doi.org/10.1136/svn-2025-004432
Documents that mention this clinical trial
Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial
https://doi.org/10.1161/strokeaha.125.052511
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke Tenecteplase II (CHABLIS-T II): rationale and design
https://doi.org/10.1136/svn-2023-002890
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024
https://doi.org/10.1136/svn-2024-003977
-
Funding
Funding for this research was provided by:
Beijing Municipal Science & Technology Committee (Z211100003521019)
Guangzhou Recomgen Biotech Co., Ltd
National Natural Science Foundation of China (81870905)
National Natural Science Foundation of China (82171272)
Beijing Hospitals Authority (PX2022019)
- License Information
